ArticleMedicine2020

Multi-center, randomized, double-blind, placebo-controlled, exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy: Study protocol clinical trial (SPIRIT Compliant).

So-Jung Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.